Cargando…

Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab

Detalles Bibliográficos
Autores principales:	Moreira Ferreira, Vanessa F., Meredith, David, Stankiewicz, James M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Clinical/Scientific Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705626/ https://www.ncbi.nlm.nih.gov/pubmed/31454764 http://dx.doi.org/10.1212/NXI.0000000000000589

Ejemplares similares

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

A Case of Relapsing-Remitting Tumefactive Demyelination
por: Wadhwa, Ankur, et al.
Publicado: (2019)

Tumefactive demyelination with a transient appearance of oligoclonal bands in MS under fingolimod
por: Okada, Kazumasa, et al.
Publicado: (2018)

Paraneoplastic recurrent tumefactive demyelination in a 62-year-old man with metastatic seminoma
por: Thebault, Simon, et al.
Publicado: (2018)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS
por: Novi, Giovanni, et al.
Publicado: (2020)

Tumefactive inflammatory lesions in juvenile metachromatic leukodystrophy
por: Meier, Kolja, et al.
Publicado: (2020)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016)

Tumefactive brain lesion with rapid cavity formation associated with anti-aquaporin-4 antibody
por: Uehara, Takuya, et al.
Publicado: (2016)

Half-dose ocrelizumab in selected patients with relapsing–remitting multiple sclerosis
por: Algahtani, Hussein, et al.
Publicado: (2023)

Aseptic Neutrophilic Meningitis With Hypoglycorrhachia Following a Single Ocrelizumab Infusion
por: Cicero, Steven, et al.
Publicado: (2021)

Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion
por: Tzartos, John S., et al.
Publicado: (2020)

Recurrent tumefactive demyelination: An unusual presentation
por: Bhargava, Amita, et al.
Publicado: (2015)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

MOG antibodies in combined central and peripheral demyelination syndromes
por: Vazquez Do Campo, Rocio, et al.
Publicado: (2018)

Ocrelizumab-induced vulvovaginal pyoderma gangrenosum in a patient with relapsing-remitting multiple sclerosis
por: Klumpp, Annika, et al.
Publicado: (2022)

Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis
por: Garcia, Alexandra, et al.
Publicado: (2023)

Chinese Guidelines for the Diagnosis and Management of Tumefactive Demyelinating Lesions of Central Nervous System
Publicado: (2017)

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
por: Palomares Cabeza, Virginia, et al.
Publicado: (2022)

Isolated Medullary Tumefactive Demyelination Masquerading as Tumor
por: Manoj,, et al.
Publicado: (2022)

Recurrent tumefactive demyelinating lesions in an elderly woman
por: Weil, Erika L., et al.
Publicado: (2022)

Tumefactive demyelinating disease with isolated spinal cord involvement
por: Makary, Mina S, et al.
Publicado: (2014)

Central nervous system tumefactive demyelinating lesions: Risk factors of relapse and follow-up observations
por: Li, Xinnan, et al.
Publicado: (2022)

Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
por: Zanghì, Aurora, et al.
Publicado: (2022)

Autopsy-proven demyelination associated with infliximab treatment
por: Bradshaw, Michael J., et al.
Publicado: (2016)

Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments
por: Brod, Staley A, et al.
Publicado: (2019)

Silent Tumefactive Demyelinating Lesions and Radiologically Isolated Syndrome
por: Ekmekci, Ozgul, et al.
Publicado: (2018)

Case Report: Paraneoplastic Tumefactive Demyelination Associated With Seminoma
por: Shiraishi, Wataru, et al.
Publicado: (2022)

Myelodysplastic syndrome with progressive multifocal predominantly pontine demyelination
por: Bhattacharyya, Shamik, et al.
Publicado: (2015)

CNS-disseminated Angiostrongylus cantonensis mimicking atypical demyelinating disease
por: Long, Daniel, et al.
Publicado: (2019)

Asymptomatic CNS demyelination related to TNF-α inhibitor therapy
por: Ali, Farwa, et al.
Publicado: (2016)

Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
por: Alharbi, Mansour A., et al.
Publicado: (2023)

Neurofascin-155 as a putative antigen in combined central and peripheral demyelination
por: Cortese, Andrea, et al.
Publicado: (2016)

Genetic Creutzfeldt-Jakob disease mimicking chronic inflammatory demyelinating polyneuropathy
por: Weckhuysen, Dorien, et al.
Publicado: (2015)

Tumefactive demyelination following herbal supplement use: Cause or coincidence?
por: Dubey, D, et al.
Publicado: (2016)

Progression of tumefactive demyelinating lesion in a child demonstrated with MRI
por: De Simone, Marta, et al.
Publicado: (2017)

AZD-1222: Tumefactive demyelinating brain lesion : case report
Publicado: (2022)

Tumefactive Demyelination—A Rare Presentation of Anti-MOG Syndrome
por: Sivadasan, Sesh, et al.
Publicado: (2022)

VALIDATION OF THE BRIEF INTERNATIONAL COGNITIVE ASSESSMENT FOR MULTIPLE SCLEROSIS (BICAMS) IN A LARGE COHORT OF RELAPSING-REMITTING MS PATIENTS
por: Drulović, Jelena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hsomel1nvjnrclra1veuuc9017